Federal Circuit vacates “skinny label” ruling
The US Court of Appeals for the Federal Circuit has withdrawn a ruling that was criticised by some commentators for enhancing the risk of patent infringement liability for certain generic pharmaceutical companies.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10